Immunotech Biopharm Ltd (HKG:6978)
Hong Kong · Delayed Price · Currency is HKD 0.3900
+0.0150 (4.00%)
Aug 26, 2026, 2:41 PM HKT
Immunotech Biopharm Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Selling, General & Admin | 38.5 | 41.04 | 44.54 | 53.22 | 97.71 | 104.25 |
Research & Development | 119.02 | 132.82 | 154.24 | 177.33 | 176.22 | 240.61 |
Other Operating Expenses | 1.88 | 1.21 | 2.12 | 0.5 | 0.29 | 0.29 |
Operating Expenses | 159.4 | 175.07 | 200.9 | 231.05 | 274.22 | 345.15 |
Operating Income | -159.4 | -175.07 | -200.9 | -231.05 | -274.22 | -345.15 |
Interest Expense | -24.55 | -6.81 | -7.49 | -8.52 | -6.14 | -3.68 |
Interest & Investment Income | 0.35 | 0.53 | 1.07 | 3.01 | 3.2 | 7.56 |
Currency Exchange Gain (Loss) | -0.63 | -0.6 | 0.22 | -0.07 | 0.09 | -6.27 |
Other Non Operating Income (Expenses) | -48.79 | -49.13 | 60.39 | -9.23 | -5.62 | 10.51 |
EBT Excluding Unusual Items | -233.01 | -231.07 | -146.71 | -245.85 | -282.69 | -337.03 |
Gain (Loss) on Sale of Investments | 83.06 | 0.19 | -19.81 | -90.01 | -24.02 | -18.79 |
Gain (Loss) on Sale of Assets | -0.84 | -0.03 | -0.04 | 0.2 | -0.64 | -0.09 |
Asset Writedown | -19.16 | - | -0.56 | - | - | 1.3 |
Other Unusual Items | - | - | -19.29 | 0.19 | -13.75 | - |
Pretax Income | -171.75 | -230.91 | -186.42 | -335.48 | -321.1 | -354.62 |
Income Tax Expense | -0 | - | 0.93 | - | - | - |
Earnings From Continuing Operations | -171.75 | -230.91 | -187.34 | -335.48 | -321.1 | -354.62 |
Minority Interest in Earnings | 0.2 | 0.12 | 0.43 | 0.66 | 2.99 | 0.39 |
Net Income | -171.55 | -230.79 | -186.91 | -334.82 | -318.11 | -354.22 |
Net Income to Common | -171.55 | -230.79 | -186.91 | -334.82 | -318.11 | -354.22 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 600 | 549 | 538 | 515 | 515 | 515 |
Shares Outstanding (Diluted) | 600 | 549 | 538 | 515 | 515 | 515 |
Shares Change | 16.69% | 2.02% | 4.58% | - | - | 15.95% |
EPS (Basic) | -0.29 | -0.42 | -0.35 | -0.65 | -0.62 | -0.69 |
EPS (Diluted) | -0.29 | -0.42 | -0.35 | -0.65 | -0.62 | -0.69 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -111.35 | -153 | -183.21 | -249.07 | -400.67 |
Free Cash Flow Per Share | - | -0.20 | -0.28 | -0.36 | -0.48 | -0.78 |
EBITDA | -108.12 | -121.61 | -141.6 | -178.83 | -231.11 | -324.33 |
D&A For EBITDA | 51.28 | 53.46 | 59.3 | 52.22 | 43.11 | 20.82 |
EBIT | -159.4 | -175.07 | -200.9 | -231.05 | -274.22 | -345.15 |